Search Results - "Marks, Randolph"

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Chee, Cheng E., Ashrani, Aneel A., Marks, Randolph S., Petterson, Tanya M., Bailey, Kent R., Melton, L. Joseph, Heit, John A.

“…Active cancer is the major predictor of venous thromboembolism (VTE) recurrence, but further stratification of recurrence risk is uncertain. In a…”
Get full text

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial by Galanis, Evanthia, Dooley, Katharine E., Keith Anderson, S., Kurokawa, Cheyne B., Carrero, Xiomara W., Uhm, Joon H., Federspiel, Mark J., Leontovich, Alexey A., Aderca, Ileana, Viker, Kimberly B., Hammack, Julie E., Marks, Randolph S., Robinson, Steven I., Johnson, Derek R., Kaufmann, Timothy J., Buckner, Jan C., Lachance, Daniel H., Burns, Terry C., Giannini, Caterina, Raghunathan, Aditya, Iankov, Ianko D., Parney, Ian F.

“…Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this…”
Get full text

Risk factors for incident venous thromboembolism in active cancer patients: A population based case–control study by Ashrani, Aneel A, Gullerud, Rachel E, Petterson, Tanya M, Marks, Randolph S, Bailey, Kent R, Heit, John A

“…Abstract Background Independent risk factors for cancer-associated incident venous thromboembolism (VTE) and their magnitude of risk are not fully…”
Get full text

Risk of site-specific cancer in incident venous thromboembolism: A population-based study by Petterson, Tanya M, Marks, Randolph S, Ashrani, Aneel A, Bailey, Kent R, Heit, John A

“…Abstract Background The risk of venous thromboembolism ( VTE ) by cancer site is uncertain. Objective To estimate VTE risk by tumor site. Methods We enumerated…”
Get full text

Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597 by KARP, Daniel D, LEE, Sandra J, OKAWARA, Gordon, MARKS, Randolph, FRECHETTE, Eric, MCCASKILL-STEVENS, Worta, LIPPMAN, Scott M, RUCKDESCHEL, John, KHURI, Fadlo R, KELLER, Steven M, WRIGHT, Gail Shaw, AISNER, Seena, BELINSKY, Steven Alan, JOHNSON, David H, JOHNSTON, Michael R, GOODMAN, Gary, CLAMON, Gerald

“…Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of…”
Get full text

Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications by Roden, Anja C, Yi, Eunhee S, Jenkins, Sarah M, Edwards, Kelly K, Donovan, Janis L, Cassivi, Stephen D, Marks, Randolph S, Garces, Yolanda I, Aubry, Marie Christine

“…The prognostic value of histopathologic classifications of thymoma is debated. Problematic reproducibility might cause this controversy. We studied the…”
Get more information

Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma by Roden, Anja C, Greipp, Patricia T, Knutson, Darlene L, Kloft-Nelson, Sara M, Jenkins, Sarah M, Marks, Randolph S, Aubry, Marie Christine, García, Joaquín J

“…A significant portion of adenoid cystic carcinoma (ACC) cases are characterized by a t(6;9)(q22-23;p23-24) translocation that originates a MYB-NFIB fusion…”
Get more information

Quality of life and symptom burden among long-term lung cancer survivors by Yang, Ping, Cheville, Andrea L, Wampfler, Jason A, Garces, Yolanda I, Jatoi, Aminah, Clark, Matthew M, Cassivi, Stephen D, Midthun, David E, Marks, Randolph S, Aubry, Marie-Christine, Okuno, Scott H, Williams, Brent A, Nichols, Francis C, Trastek, Victor F, Sugimura, Hiroshi, Sarna, Linda, Allen, Mark S, Deschamps, Claude, Sloan, Jeff A

“…Information is limited regarding health-related quality of life (QOL) status of long-term (greater than 5 years) lung cancer survivors (LTLCS). Obtaining…”
Get more information

Management of Multifocal Lung Cancer: Results of a Survey by Leventakos, Konstantinos, Peikert, Tobias, Midthun, David E, Molina, Julian R, Blackmon, Shanda, Nichols, Francis C, Garces, Yolanda I, Hallemeier, Christopher L, Murphy, Stephen J, Vasmatzis, George, Kratz, Sarah L, Holland, William P, Thomas, Charles F, Mullon, John J, Shen, K Robert, Cassivi, Stephen D, Marks, Randolph S, Aubry, Marie Christine, Adjei, Alex A, Yang, Ping, Allen, Mark S, Edell, Eric S, Wigle, Dennis, Mansfield, Aaron S

“…Multifocal lung cancer is an increasingly common clinical scenario, but there is lack of high-level evidence for its optimal treatment. Thus, we surveyed…”
Get more information

Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 by Yang, Ping, Allen, Mark S, Aubry, Marie C, Wampfler, Jason A, Marks, Randolph S, Edell, Eric S, Thibodeau, Stephen, Adjei, Alex A, Jett, James, Deschamps, Claude

“…To improve the current understanding of the etiology and natural history of primary lung cancer, we need to study the dynamic changes of clinical presentation…”
Get more information

Screening for lung cancer with low-dose spiral computed tomography by SWENSEN, Stephen J, JETT, James R, MARKS, Randolph S, CLAYTON, Amy C, PAIROLERO, Peter C, SLOAN, Jeff A, MIDTHUN, David E, HARTMAN, Thomas E, SYKES, Anne-Marie, AUGHENBAUGH, Gregory L, ZINK, Frank E, HILLMAN, Shauna L, NOETZEL, Gayle R

“…Studies suggest that screening with spiral computed tomography can detect lung cancers at a smaller size and earlier stage than chest radiography can. To…”
Get full text

Genetic variants and risk of lung cancer in never smokers: a genome-wide association study by Li, Yafei, PhD, Sheu, Chau-Chyun, MD, Ye, Yuanqing, PhD, de Andrade, Mariza, Prof, Wang, Liang, PhD, Chang, Shen-Chih, PhD, Aubry, Marie C, MD, Aakre, Jeremiah A, BS, Allen, Mark S, Prof, Chen, Feng, PhD, Cunningham, Julie M, PhD, Deschamps, Claude, Prof, Jiang, Ruoxiang, BS, Lin, Jie, PhD, Marks, Randolph S, MD, Pankratz, V Shane, PhD, Su, Li, BS, Li, Yan, MD, Sun, Zhifu, MD, Tang, Hui, PhD, Vasmatzis, George, PhD, Harris, Curtis C, MD, Spitz, Margaret R, Prof, Jen, Jin, PhD, Wang, Renyi, MPH, Zhang, Zuo-Feng, Prof, Christiani, David C, Prof, Wu, Xifeng, Prof, Yang, Ping, Dr, Prof

“…Summary Background Lung cancer in individuals who have never smoked tobacco products is an increasing medical and public-health issue. We aimed to unravel the…”
Get full text

Prognostic factors for limited-stage small cell lung cancer: A study of 284 patients by Chen, Jun, Jiang, Ruoxiang, Garces, Yolanda I, Jatoi, Aminah, Stoddard, Shawn M, Sun, Zhifu, Marks, Randolph S, Liu, Yunpeng, Yang, Ping

“…Abstract Combined modality therapy is the standard care for limited stage-small cell lung cancer (LS-SCLC) and has led to a significant improvement in…”
Get full text

Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non-Small Cell Lung Cancer in Never Smokers by XIFENG WU, LIANG WANG, CHANG, Joe Y, LU, Charles, DESCHAMPS, Claude, SU, Wu-Chou, WANG, Wen-Chang, HUANG, Ming-Shyan, CHANG, David W, YAN LI, PANKRATZ, V. Shane, MINNA, John D, YUANQING YE, WAUN KI HONG, HILDEBRANDT, Michelle A. T, CHAO AGNES HSIUNG, PING YANG, AAKRE, Jeremiah A, XIA PU, CHANG, Gee-Chen, YANG, Pan-Chyr, ROTH, Jack A, MARKS, Randolph S, LIPPMAN, Scott M

“…To identify the genetic factors that influence overall survival in never smokers who have non-small cell lung carcinoma (NSCLC), we conducted a consistency…”
Get full text

Prognostic Factors Differ by Tumor Stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group Trials by FOSTER, Nathan R, MANDREKAR, Sumithra J, SCHILD, Steven E, NELSON, Garth D, ROWLAND, Kendrith M, DEMING, Richard L, KOZELSKY, Timothy F, MARKS, Randolph S, JETT, James R, ADJEI, Alex A

“…An analysis of 14 small cell lung cancer (SCLC) trials was performed to improve the current understanding of potential prognostic factors for overall survival…”
Get full text

Reproducibility of 3 Histologic Classifications and 3 Staging Systems for Thymic Epithelial Neoplasms and Its Effect on Prognosis by Roden, Anja C, Yi, Eunhee S, Jenkins, Sarah M, Edwards, Kelly K, Donovan, Janis L, Lewis, Jean E, Cassivi, Stephen D, Marks, Randolph S, Garces, Yolanda I, Aubry, Marie Christine

“…Data regarding the prognostic significance of the histopathologic classifications of thymic epithelial neoplasms are contradictory, perhaps reflecting issues…”
Get full text

Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy by Paludo, Jonas, Fritchie, Karen, Haddox, Candace L, Rose, Peter S, Arndt, Carola A S, Marks, Randolph S, Galanis, Evanthia, Okuno, Scott H, Robinson, Steven I

“…Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum…”
Get full text

Efficacy of chest computed tomography prediction of the pathological TNM stage of thymic epithelial tumours by White, Darin B, Hora, Megan J, Jenkins, Sarah M, Marks, Randolph S, Garces, Yolanda I, Cassivi, Stephen D, Roden, Anja C

“…The aim of this study is to evaluate the efficacy of chest computed tomography (CT) to predict the pathological stage of thymic epithelial tumours (TET) using…”
Get full text

Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment by Li, Yan, Swensen, Stephen J, Karabekmez, Leman Günbey, Marks, Randolph S, Stoddard, Shawn M, Jiang, Ruoxiang, Worra, Joel B, Zhang, Fang, Midthun, David E, de Andrade, Mariza, Song, Yong, Yang, Ping

“…The contribution of emphysema to lung cancer risk has been recognized, but the effect size needs to be further defined. In this study, 565 primary lung cancer…”
Get full text

Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients by Schild, Steven E., Zhao, Liming, Wampfler, Jason A., Daniels, Thomas B., Sio, Terence, Ross, Helen J., Paripati, Harshita, Marks, Randolph S., Yi, Joanne, Liu, Han, He, Yanqi, Yang, Ping

“…This analysis was performed to describe the outcome of very elderly (≥ 80 years) patients with small-cell lung cancer (SCLC) as there is no published data…”
Get full text